Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unlike many investors foundations or other financial businesses do thorough dd before investing, loaning or giving money to a biotech.
The result is PMCB has failed the sniff test every time.
Now unlike Pharmacyte, a company called ViaCyte for example is actually enrolled in human FDA clinic trials for the same islet therapy for T1D that PMCB only dreams about.
Here's there funding.
(ViaCyte)
In addition to JDRF, the California Institute for Regenerative Medicine (CIRM)’s Alpha Clinic, the Sanford Stem Cell Clinical Center, the JDRF Canadian Clinical Trials Network (CCTN), the Stem Cell Network, and Alberta Innovates Health Solutions (AIHS) are all providing support for the trial.
http://viacyte.com/press-releases/viacyte-announces-first-patients-implanted-with-pec-direct-islet-cell-replacement-therapy-in-international-clinical-trial/
Have you heard ViaCyte just enrolled first human patients in FDA trial for t1 diabetes??
This is great news for T1 diabetics! A real company progressing with actual real trials.
[/color=red]Not so great for pmcb though..... [/color]
I took the liberty of posting this great news below for all to ENJOY!
Finally a real company (ViaCyte) that's going to treat sickness people and not exploit them to make money off of like pmcb does!
ViaCyte Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy in International Clinical Trial
San Diego, August 1, 2017 — ViaCyte, Inc., a privately-held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC-Direct™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life-threatening complications. The first implant procedures of the clinical trial took place at the University of Alberta Hospital in Edmonton, Alberta, and the UC San Diego School of Medicine’s Altman Clinical Trials Research Institute. The goal of the open-label clinical trial is to evaluate the PEC-Direct product candidate for safety and definitive evidence of efficacy. In the coming months, the company expects to expand the trial to additional centers including the University of Minnesota and other sites in the US and Canada.
The first cohort of type 1 diabetes patients is receiving multiple small-format cell-filled devices called sentinels in order to evaluate safety and implant viability. These sentinel units will be removed at specific time points and examined histologically to provide early insight into the progression of engraftment and maturation into pancreatic islet cells including insulin-producing beta cells. A second cohort of up to 40 patients is expected to begin enrolling later this year to evaluate both safety and efficacy. The primary efficacy measurement in the trial will be the clinically relevant production of insulin, as measured by the insulin biomarker C-peptide, in a patient population that has little to no ability to produce endogenous insulin at the time of enrollment. Other important endpoints will be evaluated including injectable insulin usage and the incidence of hypoglycemic events. ViaCyte’s goal is to demonstrate early evidence of efficacy in the first half of 2018 and definitive efficacy 6 to 12 months later.
“Islet transplants have been used to successfully treat patients with unstable, high-risk type 1 diabetes, but the procedure has limitations, including a very limited supply of donor organs and challenges in obtaining reliable and consistent islet preparations,” said trial investigator James Shapiro, MD, PhD, FRCSC, Director of the Clinical Islet Transplant Program, University of Alberta. “An effective stem cell-derived islet replacement therapy would solve these issues and has the potential to help a greater number of people.”
“Patients with high-risk type 1 diabetes complications, such as hypoglycemia unawareness, are at constant risk of life-threatening low blood glucose,” said Jeremy Pettus, MD, investigator in the clinical trial and Assistant Professor of Medicine at UC San Diego. “The PEC-Direct islet cell replacement therapy is designed to help patients with the most urgent medical need.”
The PEC-Direct product candidate is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or severe hypoglycemic episodes. It is estimated that about 140,000 people in Canada and the US have such high-risk type 1 diabetes. In addition to providing an unlimited supply of cells for implantation, the PEC-Direct approach has other potential advantages relative to cadaver islet transplants such as delivering a more consistent product preparation under quality-controlled cGMP conditions, and a more straightforward and safe mode of delivery.
The clinical trial is being supported in part by JDRF, the leading global organization funding type 1 diabetes research. “JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC-Direct islet cell replacement therapy,” said Derek Rapp, JDRF President and Chief Executive Officer. “JDRF is excited to support this clinical development given its potential to help those people with type 1 diabetes that need it the most – those at high risk of life-threatening acute complications. JDRF and ViaCyte share a continuing commitment to realizing the potential of beta cell replacement strategies to deliver insulin independence without immune suppression for people living with type 1 diabetes, and ultimately, at JDRF we hope this will move us forward in fulfilling our vision of a world without type 1 diabetes.”
“There are limited treatment options for patients with high-risk type 1 diabetes to manage life-threatening hypoglycemic episodes,” said Paul Laikind, PhD, President and Chief Executive Officer of ViaCyte. “We believe that the PEC-Direct product candidate has the potential to transform the lives of these patients and we are excited to move closer to that goal with the initiation of clinical evaluation announced today. This also represents a step towards a broader application of the technology. We remain fully committed to developing a functional cure for all patients with insulin-requiring diabetes. To that end, we are hard at work on next-generation approaches as well, and expect the work with PEC-Direct to further advance our knowledge and drive progress.”
In addition to JDRF, the California Institute for Regenerative Medicine (CIRM)’s Alpha Clinic, the Sanford Stem Cell Clinical Center, the JDRF Canadian Clinical Trials Network (CCTN), the Stem Cell Network, and Alberta Innovates Health Solutions (AIHS) are all providing support for the trial.
About the PEC-Direct Product Candidate
The PEC-Direct product candidate delivers stem cell-derived pancreatic progenitor cells, called PEC-01™ cells, in a device designed to allow direct vascularization of the cells in the device. After implantation, these cells are expected to become mature human islet tissue including well-regulated beta cells producing insulin on demand. The direct vascularization of the implanted cells is expected to allow for robust and consistent engraftment but will necessitate the use of maintenance immune suppression therapy.
About ViaCyte
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in a durable and retrievable cell delivery device. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two products in clinical development. The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin. ViaCyte is headquartered in San Diego, California. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
http://viacyte.com/press-releases/viacyte-announces-first-patients-implanted-with-pec-direct-islet-cell-replacement-therapy-in-international-clinical-trial/
Pmcb lost to Viacyte for T1 diabetes.
VC-01ViaCyte is developing islet cell replacement therapy for insulin-requiring diabetes. Our two key products in development deploy the same active component, PEC-01 Cells, but with different delivery technologies and addressing the unmet needs of different patient groups.
The Human Trial is an independent, feature-length documentary that is in the works, currently following ViaCyte’s quest to develop what might become a functional cure for type 1 diabetes (T1D).
http://viacyte.com
Looks promising for viacyte, not so much for pharmacyte.
So much for Austrianova producing for FDA fantasy trial. Looks like pmcb has found another excuse for delaying at least another year.
Wow pretty much blows CIAB early results away.
"Eleven patients are still alive. The median overall survival rate of 16.5 months exceeds the historical average survival of six-12 months with standard chemotherapy.
Seventeen of 24 patients - 71 percent - had a reduction in tumor size of at least 30 percent.
Two of those 17 patients had a complete response - no detectable tumor."
http://www.mdpi.com/1999-4923/6/3/447/pdf
I believe overestimating. Although it might be a heroic attempt I believe it would fall on deaf and greedy ears.
Let's see.
A. Pmcb gets emails, calls complaining about dilution so they stop.
B. Pmcb ignores investors and continues collect millions by selling shares at wholesale.
I'll bet B.
That's what the intelligent do.
Quote:
"It's always good to ask isn't it?"
Pmcb is and has been counting on the average joe just buying without questioning. To believe everything they say without questions.
Good to see some investors finally asking, demanding answers from pmcb in its shady practices. It's to bad they'll never get an honest answer and although it's shady BULLSHIT theirs nothing illegal about the issuances. Those on the know win, retail lose.
We? No I do know that. Carlos A. Trujillo, and Tim Matula, Joseph Fiore to name a few. Google em. Kenny boy gave a shit load of warrants out not to long ago to fiore.
The couple "respected doctors" mainly from Td2 have no part of pmcb business side. If anything they would be considered victims as well as all the retail. Now Crabtree wouldn't be but we're also talking about respected doctors here.
No, then they would award the shares aka give them away for FREE like all the other free stock, warrants, options they hand out like candy.
Kind of like this one with Thomas Liquard
“4.2. Equity Grants. Commencing on the anniversary date of the Effective Date, you will be issued annually: (i) 250,000 fully-paid, non-assessable shares of the Company’s common stock (“Shares”); and (ii) a five-year option to purchase 250,000 shares of the Company’s common stock at an exercise price equal to the fair market value of the Company’s common stock on the date of grant (“Option”). The Shares and Option will be fully vested as of the date of grant. The Company will issue you an option agreement in the Company’s standard form to evidence the Option.
https://www.sec.gov/Archives/edgar/data/1157075/000168316817000541/pharmacyte_10q-ex1007.htm
Quote:
"When they sell shares for .03, it's not because they need money it's to reward someone. The reward should come when they succeed. Still long and positive because of the credibility of the doctors."
It's really strange or it's one big Fing coincidence how a few of these ppl have been associated with pmcb CEO Kenny boy and his past shady scam (China-tel). Such a small world.
Quote:
"Bunch of unnamed people gets hundreds of thousands of shares each at below market value. Invest at your own risk."
Now that Pmcb has diluted its retail at a billion shares a REVERSE SPLIT is guaranteed.
Pmcb has no funding through Chardan as long as their market cap is below $75m.
This leaves pmcb with no choice but to continue selling shares vast quantities of shares at HUGE discounts 50%+ further expediting the O/S count.
At the rate pmcb is offloading shares their piggy bank of 1.4 A/S is almost gone.
Current shareholders will be wiped out!!
Repeat,
WIPED OUT!!!!!
Bullshit! Pure fantasy. Pmcb has nothing that Janssen would want.
Quote:
"he has brought the deal to the table with janssen."
Here's a good read for those who think pmcb has to be legit.
"When biotech goes bad"
http://www.readcube.com/articles/10.1038/nbt.3510
Like I said, again.. I posted this a while ago. Only reposted because 1234 wanted proof of pmcb screwing its investors.
Bingo!
"the statement from KW friend saying they made ten fold over the last 4 years make sense now....."
Pmcb had the s-3 available for the majority of the years to be able to sell at market value yet they still chose to not always sell through Chardan and instead sell them at cheap discounts to their buddies.
No nda with janssen only pmcb's crew. All in the sec filings. The jnj report was done by pmcb buddy Ken Kerr at stock market media group who have been previously paid in hundreds of thousands of shares.
The rest is throwing mud at a wall and hoping it sticks. Better odds in the lotto.
Like I said I posted that a while ago and only shared it again as a request to "back up" my statement that pmcb has been selling shares at a discount for years.
I could go through all the latest financials to give you more current but I don't really feel like it at this moment besides I don't think it would change your perspective regardless...
But, If you really want to know go to
https://www.sec.gov/cgi-bin/browse-edgar?company=PharmaCyte&owner=exclude&action=getcompany
Start looking through the 10q & k's. (Hint) To make it faster use your browser word search and search each report for keyword such as "company sold".
Take the amounts look up the pps and you will find your answer to how hard pmcb is ramming it up its retail investors.
You can check the historical pps at the time of each sale to see the discounts they were sold at if you need further proof.
Ive posted that long ago here. I know your new so didn't expect you to have seen it.
On January 21, 2014, the Company sold 7,000,000 shares of common stock to an accredited investor for total cash proceeds of $500,000.
On January 29, 2014, the Company sold 500,000 shares of common stock to an accredited investor for total cash proceeds of $50,000.
On February 4, 2014, the Company sold 100,000 shares of common stock to an accredited investor for total cash proceeds of $10,000.
On February 14, 2014, the Company sold 8,000,000 shares of common stock to Lincoln Park Capital Fund, LLC (“Lincoln Park”) for total cash proceeds of $2,000,000.
On February 18, 2014, the Company sold 1,000,000 shares of common stock to an accredited investor for total cash proceeds of $100,000.
On February 26, 2014, the Company sold 50,000 shares of common stock to an accredited investor for total cash proceeds of $5,000.
On February 28, 2014, the Company sold 10,000,000 shares of common stock to an accredited investor for total cash proceeds of $1,000,000.
On March 11, 2014, the Company sold 50,000 shares of common stock to an accredited investor for total cash proceeds of $5,000.
During February 2014, the Company converted outstanding Class A warrants into 15,204,600 shares of common stock for total cash proceeds of $1,140,345.
During March 2014, the Company converted outstanding Class A and Class B warrants into 4,045,000 shares of common stock for total cash proceeds of $359,175.
During April 2014, the Company converted outstanding Class B warrants into 528,000 shares of common stock for total cash proceeds of $63,360.
This isn't the first time. They've been screwing retail for years by selling shares at huge discounts.
How ya feel about KW going from a base salary of 180k in 2015 to 375k now? 108% increase!!
Meanwhile investing in pmcb has been like throwing money out the window.
It was a theory a few years ago and it failed miserably. Hence pmcb's share price is so embarrassingly low.
And
We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
There are several large pharmaceutical and biotechnology companies that currently market products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are the same as or are like our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.
Specifically, there are numerous companies developing or marketing therapies for cancer and diabetes, including many major pharmaceutical and biotechnology companies. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we can enter the market.
33
Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology sectors may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Standard for pmcb? I just checked a few yearly financial reports from other biotechs jnj celg gild icpt to name a few and didn't find that disclaimer anywhere in theirs.
We intend to conduct clinical trials for certain of our product candidates at sites outside of the U.S., and the U.S. regulatory agencies may not accept data from trials conducted in such locations.
Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to certain conditions imposed by the regulatory agencies outside of the U.S. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the population in the country in which the clinical trial is being conducted. The data must be applicable to the U.S. population and medical practice in the U.S. in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the U.S. must be representative of the population for whom we intend to seek approval in the U.S.
In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the U.S. If the FDA does not accept the data from any of our clinical trials that we determine to conduct outside the U.S., it would likely result in the need for additional trials that would be costly and time-consuming and delay or permanently halt our development of the product candidate.
In addition, the conduct of clinical trials outside the U.S. could have a significant impact on us. Risks inherent in conducting international clinical trials include:
Foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;
Administrative burdens of conducting clinical trials under multiple foreign regulatory schemes;
Foreign exchange fluctuations;
Diminished protection of intellectual property in some countries.
We intend to seek FDA approval to commence clinical trials in the U.S. of certain of our product candidates based on clinical data that was obtained in trials conducted outside the U.S., and it is possible that the FDA may not accept data from trials conducted in such locations.
We intend to seek FDA acceptance of an IND to commence a pivotal clinical trial in LAPC using genetically engineered live human cells encapsulated using our Cell-in-a-Box® technology in combination with ifosfamide. A Phase 1/2 clinical trial and a Phase 2 clinical trial were previously conducted using the same technology in combination with ifosfamide between 1998 and 1999 and between 1999 and 2000, respectively. The Phase 1/2 clinical trial was carried out at the Division of Gastroenterology, University of Rostock, Germany, and the Phase 2 clinical trial was carried out at four centers in two countries in Europe: Berne, Switzerland, and in Rostock, Munich and Berlin, Germany.
Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to certain conditions imposed by the FDA. There is a risk that the FDA may not accept the data from the two previous trials. In that case, we may be required to conduct a Phase 1 or a Phase 1/2B clinical trial rather than the planned pivotal clinical trial in LAPC, which may result in additional costs to us and resultant delays in the regulatory review process and any future commercialization and marketing, if regulatory approval is obtained. It is not known whether the FDA would be likely to reject the use of such clinical data due to the time that has elapsed since such trials were conducted or because the clinical trial material for our proposed pivotal clinical trial is slightly different from that used in the earlier clinical trials because of cloning the cells used in the earlier trials and certain other modifications and improvements that have been made to the Cell-in-a-Box® technology since the time of the earlier trials.
Pmcb acquired the license to jump on the mj train a few years back. They were late to the party as the mj stocks were declining. Nothing will ever come of this, timeframe = never. Only revenue is the cash pmcb management collects upon selling shares after pumping to the mj investors. Company sold/gave away 97,859,201 shares last quarter alone.
973,167,811 shares outstanding as of July27th 2017!!!!
Quote:
"Can anyone explain the potential revenue stream and time frame from this?"
Ya that's it... Hey I'm sure pmcb was bought out already for 50b but investors don't know because Kenny boy "probably signed nda".....
Since 2003 Pmcb has been creating:
(Delusion) "A fixed false belief that is resistant to reason or confrontation with actual fact: a paranoid delusion."
(Delusional)
"A false belief strongly held in spite of invalidating evidence, especially as a symptom of mental illness."
Quote:
"I've racked my brains. He's teasing us. Wants to tell exciting news but probably signed nda. So he's dropped a hint as he's probably incredibly excited.
Wants us all to know too."
Hmm for some reason Pmcb is only claiming 4 employees according to their last 10k.
"As of April 30, 2016, we had four full-time employees and three consultants who function as our Chief Scientific Officer, our Director of Diabetes Program Development and the Chairman of our Advisory Board. We use consulting scientists, physicians, academics and other professionals for the majority of our research, clinical development and operations."
https://www.sec.gov/Archives/edgar/data/1157075/000101968716007057/pharmacyte_10k-043016.htm
Ken and his old lady are on another skiing vacation up in Canada. Canada celebrating 150th anniversary this year. Somehow when Ken boy posts pictures of how he's having fun spending shareholders cash delusions set in to think there's something more going on. Joke is in the shareholders who who try turning a picture into something it's not. Na, Kenny boy wouldn't screw his investors right? Wrong.
Everyone's entitled to their own opinion. I choose to believe the product that big money is backing and actually is in FDA trials as to those companies that sells dreams.
Quote:
Mellingen cells are superior to Islet and beta cells
Nordisk is working with JDRF and their BETA CELL. Pmcb was an epic fail according to Nordisk. Apparently the technology pmcb is pushing sucks and is the laughing stock of the pharma field.
Yes and JDRF has it. It's called BETA CELL! Superior to CIAB. That's why BETA CELL has big money backing its development. CIAB has uh uh, hmm nobody.
Quote:
"Looking for the world's best cell encapsulation?"
http://www.jdrf.org/research/beta-cell-replacement/
Nope. JDRF has what pmcb wishes they had (beta cell) and plenty of cash.
JDRF "Our pioneering research
Successful encapsulated beta cell replacement therapies will bring the same benefits as islet cell transplantation—a treatment that, not long ago, created tremendous excitement in the T1D community. Research has shown that many recipients of these transplants can achieve normalized blood-glucose control for up to five years or longer. But widespread use of islet transplants is not possible for two reasons: not enough islets are available; and transplant recipients must take powerful drugs to prevent the immune system from destroying the transplanted cells. Encapsulated beta cell replacement therapies have the potential to overcome both obstacles.
Beta cells are the islet cells responsible for producing insulin. JDRF has been a driving force behind beta cell replacement research that could make beta cell replacement a widely available option for people with T1D. To date, our efforts have resulted in techniques for scaling up production of implantable cells that can become islets, the design of beta cell replacement materials that show promise in blocking an immune system attack and the launch of human clinical trials to test the safety and efficacy of these therapies."
It's hard to do if bought on November pump. Pps has been falling since.